During Q2, biopharma merger and acquisition deal value reached $22.2bn and drew in $36.3bn in potential deal value from alliances. Device company M&A values reached $21.3bn, while in vitro diagnostics and research tools players’ M&A activity totaled $631.6m.
Biopharma merger and acquisition value for the second quarter of 2024 reached $22.2bn from 34 transactions, 20 of which had disclosed values. Making up almost 22% of that total was Vertex Pharmaceuticals’ $4.9bn buy of public biotech Alpine Immune Sciences. Along with this deal, seven other transactions hit or exceeded the billion-dollar mark during Q2 (see Exhibit 1).
The Vertex/Alpine Immune Sciences deal was the largest M&A of the quarter. Alpine was founded in 2015 to develop therapies...
An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.
Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.
When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.
